https://rjc2792inhibitor.com/i....nnate-carried-out-fa
A randomized trial will evaluate patients with CRPC exhibiting oligometastases, specifically three or fewer bone lesions detectable via whole-body MRI, including diffusion-weighted imaging (WB-DWI). These patients will be allocated in a 1:1 ratio to receive either radiotherapy for active metastases plus radium-223 or radiotherapy alone for the same active metastases. The historical application of androgen receptor axis-targeted therapy and the prostate-specific antigen doubling time will
Me gusta
Comentario
Compartir
